Evidence map›Paper›PMID 26510688›Full record

ArticleGene therapy2016

Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.

L Samaranch, P Hadaczek, A P Kells, J R Bringas, D Stockinger, W San Sebastian, M Macayan, S Samineni, P Pivirotto, J Forsayeth and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

L SamaranchDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8151-473X
P HadaczekDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
A P KellsDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
J R BringasDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
D StockingerValley Biosystems, West Sacramento, CA, USA.
W San SebastianDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
M MacayanDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
S SamineniValley Biosystems, West Sacramento, CA, USA.
P PivirottoDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
J ForsayethDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
K S BankiewiczDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

Translational AAV Delivery Platform to the BrainR01NS073940 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANKIEWICZ, KRYSTOF S · 2011 to 2015
$2.8M
NINDS NIH HHS R01NS073940-01
6 · The paper itself

Abstract

Adeno-associated virus serotype 2 (AAV2) has previously been reported to be a slowly uncoating virus in peripheral tissues, but persistence of intact vector in primate brain has not been explored. Because some neurological gene therapies may require re-administration of the same vector to patients, it seems important to understand the optimal timeframe in which to consider such repeat intervention. Surprisingly, convection-enhanced delivery of AAV2 into the thalamus of nonhuman primates (NHPs) resulted in robust staining of neurons with A20 antibody that detected intact AAV2 particles at ∼1.5 months after infusion. However, by 2.5 months, no A20 staining was visible. These data confirmed earlier findings of persistence of intact AAV2 particles in ocular and hepatic tissues. In order to probe the potential consequences of this persistence, we infused AAV2-human aromatic L-amino acid decarboxylase into left and right thalamus of three NHPs, with a 3-month delay between infusions. During that interval, we immunized each animal subcutaneously with AAV2 virus-like particles (empty vector) in order to induce strong anti-capsid humoral immunity. Various high neutralizing antibody titers were achieved. The lowest titer animal showed infiltration of B lymphocytes and CD8(+) T cells into both the secondary and primary infusion sites. In the other two animals, extremely high titers resulted in no transduction of the second site and, therefore, no lymphocytic infiltration. However, such infiltration was prominent at the primary infusion site in each animal and was associated with overt neuronal loss and inflammation.

Indexed as

AnimalsBrainCapsidCapsid ProteinsCD8-Positive T-LymphocytesDependovirusGenetic TherapyGenetic VectorsGene Transfer TechniquesMacaca mulattaMalePrimatesTransduction, GeneticCapsid Proteins

Identifiers

PMID26510688
OpenAlexW2195306609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.